The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
T-Cell Therapy-Global Market Insights and Sales Trends 2024
Synopsis
The global T-Cell Therapy market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of T-Cell Therapy in various end use industries. The expanding demands from the Hospitals, Clinics & Ambulatory Centers, Cancer Research Institutes and Others, are propelling T-Cell Therapy market. CAR T Cell Therapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the TCR Therapy segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for T-Cell Therapy market, driven by demand from China, the second largest economy with some signs of stabilising, the T-Cell Therapy market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for T-Cell Therapy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global T-Cell Therapy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global T-Cell Therapy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, T-Cell Therapy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of T-Cell Therapy covered in this report include Gilead Sciences, Inc., Sorrento Therapeutics, Fate Therapeutics Inc., Novartis International AG, AbbVie Inc., Adaptimmune Therapeutics PLC, Bluebird Bio, TCR2 Therapeutics, Inc. and Pfizer Inc., etc.
The global T-Cell Therapy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Gilead Sciences, Inc.
Sorrento Therapeutics
Fate Therapeutics Inc.
Novartis International AG
AbbVie Inc.
Adaptimmune Therapeutics PLC
Bluebird Bio
TCR2 Therapeutics, Inc.
Pfizer Inc.
DiaCarta, Inc.
Global T-Cell Therapy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global T-Cell Therapy market, Segment by Type:
CAR T Cell Therapy
TCR Therapy
TIL Therapy
Global T-Cell Therapy market, by Application
Hospitals
Clinics & Ambulatory Centers
Cancer Research Institutes
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of T-Cell Therapy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global T-Cell Therapy market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of T-Cell Therapy in various end use industries. The expanding demands from the Hospitals, Clinics & Ambulatory Centers, Cancer Research Institutes and Others, are propelling T-Cell Therapy market. CAR T Cell Therapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the TCR Therapy segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for T-Cell Therapy market, driven by demand from China, the second largest economy with some signs of stabilising, the T-Cell Therapy market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for T-Cell Therapy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global T-Cell Therapy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global T-Cell Therapy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, T-Cell Therapy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of T-Cell Therapy covered in this report include Gilead Sciences, Inc., Sorrento Therapeutics, Fate Therapeutics Inc., Novartis International AG, AbbVie Inc., Adaptimmune Therapeutics PLC, Bluebird Bio, TCR2 Therapeutics, Inc. and Pfizer Inc., etc.
The global T-Cell Therapy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Gilead Sciences, Inc.
Sorrento Therapeutics
Fate Therapeutics Inc.
Novartis International AG
AbbVie Inc.
Adaptimmune Therapeutics PLC
Bluebird Bio
TCR2 Therapeutics, Inc.
Pfizer Inc.
DiaCarta, Inc.
Global T-Cell Therapy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global T-Cell Therapy market, Segment by Type:
CAR T Cell Therapy
TCR Therapy
TIL Therapy
Global T-Cell Therapy market, by Application
Hospitals
Clinics & Ambulatory Centers
Cancer Research Institutes
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of T-Cell Therapy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of T-Cell Therapy
1.1 T-Cell Therapy Market Overview
1.1.1 T-Cell Therapy Product Scope
1.1.2 T-Cell Therapy Market Status and Outlook
1.2 Global T-Cell Therapy Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global T-Cell Therapy Market Size by Region (2018-2029)
1.4 Global T-Cell Therapy Historic Market Size by Region (2018-2023)
1.5 Global T-Cell Therapy Market Size Forecast by Region (2024-2029)
1.6 Key Regions, T-Cell Therapy Market Size (2018-2029)
1.6.1 North America T-Cell Therapy Market Size (2018-2029)
1.6.2 Europe T-Cell Therapy Market Size (2018-2029)
1.6.3 Asia-Pacific T-Cell Therapy Market Size (2018-2029)
1.6.4 Latin America T-Cell Therapy Market Size (2018-2029)
1.6.5 Middle East & Africa T-Cell Therapy Market Size (2018-2029)
2 T-Cell Therapy Market by Type
2.1 Introduction
2.1.1 CAR T Cell Therapy
2.1.2 TCR Therapy
2.1.3 TIL Therapy
2.2 Global T-Cell Therapy Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global T-Cell Therapy Historic Market Size by Type (2018-2023)
2.2.2 Global T-Cell Therapy Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America T-Cell Therapy Revenue Breakdown by Type (2018-2029)
2.3.2 Europe T-Cell Therapy Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific T-Cell Therapy Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America T-Cell Therapy Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa T-Cell Therapy Revenue Breakdown by Type (2018-2029)
3 T-Cell Therapy Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics & Ambulatory Centers
3.1.3 Cancer Research Institutes
3.1.4 Others
3.2 Global T-Cell Therapy Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global T-Cell Therapy Historic Market Size by Application (2018-2023)
3.2.2 Global T-Cell Therapy Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America T-Cell Therapy Revenue Breakdown by Application (2018-2029)
3.3.2 Europe T-Cell Therapy Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific T-Cell Therapy Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America T-Cell Therapy Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa T-Cell Therapy Revenue Breakdown by Application (2018-2029)
4 T-Cell Therapy Competition Analysis by Players
4.1 Global T-Cell Therapy Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in T-Cell Therapy as of 2022)
4.3 Date of Key Players Enter into T-Cell Therapy Market
4.4 Global Top Players T-Cell Therapy Headquarters and Area Served
4.5 Key Players T-Cell Therapy Product Solution and Service
4.6 Competitive Status
4.6.1 T-Cell Therapy Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Gilead Sciences, Inc.
5.1.1 Gilead Sciences, Inc. Profile
5.1.2 Gilead Sciences, Inc. Main Business
5.1.3 Gilead Sciences, Inc. T-Cell Therapy Products, Services and Solutions
5.1.4 Gilead Sciences, Inc. T-Cell Therapy Revenue (US$ Million) & (2018-2023)
5.1.5 Gilead Sciences, Inc. Recent Developments
5.2 Sorrento Therapeutics
5.2.1 Sorrento Therapeutics Profile
5.2.2 Sorrento Therapeutics Main Business
5.2.3 Sorrento Therapeutics T-Cell Therapy Products, Services and Solutions
5.2.4 Sorrento Therapeutics T-Cell Therapy Revenue (US$ Million) & (2018-2023)
5.2.5 Sorrento Therapeutics Recent Developments
5.3 Fate Therapeutics Inc.
5.3.1 Fate Therapeutics Inc. Profile
5.3.2 Fate Therapeutics Inc. Main Business
5.3.3 Fate Therapeutics Inc. T-Cell Therapy Products, Services and Solutions
5.3.4 Fate Therapeutics Inc. T-Cell Therapy Revenue (US$ Million) & (2018-2023)
5.3.5 Novartis International AG Recent Developments
5.4 Novartis International AG
5.4.1 Novartis International AG Profile
5.4.2 Novartis International AG Main Business
5.4.3 Novartis International AG T-Cell Therapy Products, Services and Solutions
5.4.4 Novartis International AG T-Cell Therapy Revenue (US$ Million) & (2018-2023)
5.4.5 Novartis International AG Recent Developments
5.5 AbbVie Inc.
5.5.1 AbbVie Inc. Profile
5.5.2 AbbVie Inc. Main Business
5.5.3 AbbVie Inc. T-Cell Therapy Products, Services and Solutions
5.5.4 AbbVie Inc. T-Cell Therapy Revenue (US$ Million) & (2018-2023)
5.5.5 AbbVie Inc. Recent Developments
5.6 Adaptimmune Therapeutics PLC
5.6.1 Adaptimmune Therapeutics PLC Profile
5.6.2 Adaptimmune Therapeutics PLC Main Business
5.6.3 Adaptimmune Therapeutics PLC T-Cell Therapy Products, Services and Solutions
5.6.4 Adaptimmune Therapeutics PLC T-Cell Therapy Revenue (US$ Million) & (2018-2023)
5.6.5 Adaptimmune Therapeutics PLC Recent Developments
5.7 Bluebird Bio
5.7.1 Bluebird Bio Profile
5.7.2 Bluebird Bio Main Business
5.7.3 Bluebird Bio T-Cell Therapy Products, Services and Solutions
5.7.4 Bluebird Bio T-Cell Therapy Revenue (US$ Million) & (2018-2023)
5.7.5 Bluebird Bio Recent Developments
5.8 TCR2 Therapeutics, Inc.
5.8.1 TCR2 Therapeutics, Inc. Profile
5.8.2 TCR2 Therapeutics, Inc. Main Business
5.8.3 TCR2 Therapeutics, Inc. T-Cell Therapy Products, Services and Solutions
5.8.4 TCR2 Therapeutics, Inc. T-Cell Therapy Revenue (US$ Million) & (2018-2023)
5.8.5 TCR2 Therapeutics, Inc. Recent Developments
5.9 Pfizer Inc.
5.9.1 Pfizer Inc. Profile
5.9.2 Pfizer Inc. Main Business
5.9.3 Pfizer Inc. T-Cell Therapy Products, Services and Solutions
5.9.4 Pfizer Inc. T-Cell Therapy Revenue (US$ Million) & (2018-2023)
5.9.5 Pfizer Inc. Recent Developments
5.10 DiaCarta, Inc.
5.10.1 DiaCarta, Inc. Profile
5.10.2 DiaCarta, Inc. Main Business
5.10.3 DiaCarta, Inc. T-Cell Therapy Products, Services and Solutions
5.10.4 DiaCarta, Inc. T-Cell Therapy Revenue (US$ Million) & (2018-2023)
5.10.5 DiaCarta, Inc. Recent Developments
6 North America
6.1 North America T-Cell Therapy Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe T-Cell Therapy Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific T-Cell Therapy Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America T-Cell Therapy Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa T-Cell Therapy Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 T-Cell Therapy Market Dynamics
11.1 T-Cell Therapy Industry Trends
11.2 T-Cell Therapy Market Drivers
11.3 T-Cell Therapy Market Challenges
11.4 T-Cell Therapy Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
